Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01468623 · ClinicalTrials.gov registry record · Phase 4
Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6
A Phase 4 study, sponsored by Myriad Genetic Laboratories.
- Terminated
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT01468623: Clinical Trial Phase 4 study, sponsored by Myriad Genetic Laboratories.
NCT01468623 is a Phase 4 study that was terminated before completion, run by Myriad Genetic Laboratories. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01468623, a Phase 4 study, was terminated before completion, sponsored by Myriad Genetic Laboratories.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to compare OnDose® based pharmacokinetic administration of 5-FU versus standard Body Surface Area (BSA) based administration of 5-FU in patients with metastatic colorectal cancer treated with mFOLFOX6, with or without bevacizumab, to determine if the use of OnDose® achieves an improvement in the Overall Response Rate (ORR) relative to BSA dosing response.
Interventions
- OTHER Standard of care
- OTHER Pharmacokinetic 5-FU dose adjustment using OnDose® assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01468623
The ClinicalTrials.gov registry entry for NCT01468623 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myriad Genetic Laboratories, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of care is the first listed.
NCT01468623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01468623 about?
NCT01468623 is a clinical study titled "Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6". The purpose of this study is to compare OnDose® based pharmacokinetic administration of 5-FU versus standard Body Surface Area (BSA) based administration of 5-FU in patients with metastatic colorectal cancer treated with mFOLFOX6, with or without bevacizumab, to determine if the use of OnDose® achie...
What is the current status of trial NCT01468623?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2011-09. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01468623?
The interventions under investigation include: Standard of care (OTHER), Pharmacokinetic 5-FU dose adjustment using OnDose® assay (OTHER).
Who is sponsoring clinical trial NCT01468623?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.